Eagle Point Q2 2026 slides: NAV rebounds 8% amid CLO recovery

Emcure Pharmaceuticals reported a 23% revenue increase in the first quarter. Ebitda grew 25.8% with improved margins, reflecting productivity gains. Net profit saw a significant 36.2% rise during the period. The company began its five-year plan on a strong footing for FY27. Emcure also completed the acquisition of a minority stake in Gennova Biopharmaceuticals.

Indian stock markets saw significant gains on Monday, with the Sensex and Nifty rising approximately one percent. This surge followed US President Donald Trump’s announcement of upcoming talks with Iran, which lowered oil prices. Major companies like IndiGo and ITC experienced substantial increases, contributing to the market’s upward movement. Sectors such as FMCG and Metal…

Market participants estimate the Kusumgar IPO’s grey market premium at around Rs 162, or nearly 39% above the upper issue price of Rs 419 per share. This implies an estimated listing price of about Rs 581.